Treatment resistance and metastasis depend on cellular plasticity. In this process the cancer cells switch from a non-motile and well-differentiated phenotype to a migratory and de-differentiated phenotype. We are investigating the intrinsic and extrinsic factors/mechanisms involved in such cellular plasticity aiming to identify molecular nodes that can be utilized as targets for anti-cancer treatment. The project group headed by Prof Kristin Austlid Taskén is studying neuronal differentiation of prostate cancer, while the Lina Prasmickaite project group is focusing on phenotype switching in breast cancer and melanomas.
Mechanism of cellular uptake and cytotoxicity of paclitaxel loaded lipid nanocapsules in breast cancer cells
Int J Pharm, 597, 120217 (in press)
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)